C. Difficile

A recent publication describes the results of a clinician survey conducted in 2024 regarding preferences and actual practices in the management of C difficile infection in adults.

The financing supports phase 3 evaluation of Sidiprev, a first-in-class, nonantibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.

This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.

C difficile remains a major healthcare-associated infection. Despite clear guidelines, hand hygiene compliance often falls short, creating gaps between policy and practice. A case study from a hospital showed that after implementing an electronic hand hygiene monitoring system with behavior prompts, compliance improved.

Systematic review finds FMT and standardized microbiome products outperform antibiotics in efficacy and safety.

C difficile carriers faced a higher baseline risk for hospital-onset infection compared to noncarriers, and this risk was not significantly influenced by antibiotic use.

This week, predictive microbiome models for C difficile, synergistic antibiotic strategies for E faecalis, to pharmacy-led hepatitis C care, and more.

A new study finds that personalized gut microbiome models may predict C difficile colonization risk and guide targeted probiotic treatment.

The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.

This week, a mother's struggle with C difficile during pregnancy, racial disparities in COVID-19 treatment, Supreme Court decision preserving access to HIV prevention, and more.

Sara Embry discusses her experience with the infection while pregnant and as a mother to young children as well as finding the Peggy Lillis Foundation to help her cope with the infection and subsequently work as a peer support volunteer for the organization.

The role of oral vancomycin in preventing recurrence of C difficile infection (CDI) in at-risk persons receiving systemic antibiotic for non-CDI infection remains unclear after randomized trial.

This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.

Findings from a multicenter US study confirm that RBL is a safe and effective microbiota-based therapy with sustained remission in a high-risk population with comorbidities.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

At ASM Microbe 2025, researchers underscored the role of NAAT in outpatient CDI diagnosis and raised concerns over PPI-related risk in older, health care–associated cases.

A study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.

Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adherence.

Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies.

Lumen Bioscience’s LMN-201 was considered safe and well tolerated, and there were no severe dose-related or serious adverse events reported.

Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.

Nature Medicine published additional data on Vedanta Biosciences’ Clostridioides difficile investigational therapy, VE303, from its phase 2 trial.

Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.

CEO Larry D Sutton, MD, PhD, elaborates on the company's strategy and the science behind SIDIPREV to prevent C difficile infections in hospitalized patients.

Here are some of the bigger stories on this topic from this year.